Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Journal: Vaccine
PMID: 29279281

Abstract

INTRODUCTION: In older adults, prior administration of 23-valent pneumococcal polysaccharide vaccine (PPSV23) blunts the opsonophagocytic antibody (OPA) response to subsequent administration of 13-valent pneumococcal conjugate vaccine (PCV13). To determine whether a higher dose of PCV13 could mitigate this effect in adults 55 through 74 years of age, we compared OPA responses to a double dose of PCV13 in persons previously vaccinated with PPSV23 with responses to a single dose of PCV13 in previously vaccinated persons, and with a single dose in PPSV23 naïve persons.

Authors

  • Lisa A Jackson
    Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States. Electronic address: Jackson.L@ghc.org.
  • Hana M El Sahly
    Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, TX, United States.
  • Sarah George
    Division of Infectious Diseases, Allergy, & Immunology, Saint Louis University School of Medicine, and St. Louis VA Medical Center, St. Louis, MO, United States.
  • Patricia Winokur
    University of Iowa and Iowa City VA Medical Center, Iowa City, IA, United States.
  • Kathryn Edwards
    Vanderbilt Vaccine Research Program, Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States.
  • Rebecca C Brady
    Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • Nadine Rouphael
    The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur, GA, United States.
  • Wendy A Keitel
    Departments of Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, Houston, TX, United States.
  • Mark J Mulligan
    The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur, GA, United States.
  • Robert L Burton
    Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
  • Aya Nakamura
    The Emmes Corporation, Rockville, MD, United States.
  • Jennifer Ferreria
    The Emmes Corporation, Rockville, MD, United States.
  • Moon H Nahm
    Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.

Keywords

External Resources

Popular Topics
Recent Journals